



DEAL REPORT

Hengeler Mueller advises UCB on strategic alliance with Willex

Hengeler Mueller advised the Belgian pharmaceutical company UCB Pharma S.A. on entering into a strategic partnership with the listed biopharmaceutical company Willex AG, Munich. By way of in kind capital increase of Willex AG, UCB Pharma S.A. will contribute through a subsidiary the entire world-wide preclinical oncology development portfolio into Willex AG. In return, UCB Pharma S.A. will obtain a shareholding in Willex AG of 13.19% in the future share capital.

The Hengeler Mueller team included partners Andreas Austmann and Carsten Schapmann (both Corporate/M&A, Düsseldorf), counsel Andrea Schlaffge (Intellectual Property, Düsseldorf) as well as associates Sebastian Lochen and Patrick H. Wilkening (both Düsseldorf).

Contact: Keith D. Bain
- PR Manager -
Hengeler Mueller
Partnerschaft von Rechtsanwälten

Bockenheimer Landstrasse 24
60323 Frankfurt
Tel.: +49 69 17095-207
Fax: +49 69 725773
keith.bain@hengeler.com

12 January 2009

HENGELER MUELLER

www.hengeler.com